Allspring Global Investments Holdings LLC Has $401,000 Position in Catalent, Inc. (NYSE:CTLT)

Allspring Global Investments Holdings LLC reduced its stake in Catalent, Inc. (NYSE:CTLT) by 4.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,920 shares of the company’s stock after selling 416 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Catalent were worth $401,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. International Assets Investment Management LLC acquired a new stake in shares of Catalent in the 4th quarter valued at approximately $6,720,000. Americana Partners LLC acquired a new stake in Catalent during the 4th quarter worth approximately $2,569,000. Arizona State Retirement System boosted its position in Catalent by 0.7% during the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after buying an additional 365 shares during the period. Tran Capital Management L.P. boosted its position in Catalent by 12.2% during the 4th quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after buying an additional 39,208 shares during the period. Finally, Raymond James & Associates boosted its position in Catalent by 23.2% during the 4th quarter. Raymond James & Associates now owns 149,279 shares of the company’s stock worth $6,707,000 after buying an additional 28,106 shares during the period.

Analysts Set New Price Targets

Several research firms recently commented on CTLT. StockNews.com began coverage on shares of Catalent in a research report on Saturday. They set a “sell” rating on the stock. Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Barclays raised their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Finally, UBS Group restated a “neutral” rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $52.46.

Catalent Stock Performance

NYSE:CTLT opened at $55.92 on Friday. The company has a fifty day moving average of $56.73 and a 200-day moving average of $48.58. The firm has a market capitalization of $10.12 billion, a P/E ratio of -8.22, a P/E/G ratio of 6.04 and a beta of 1.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $60.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business’s revenue was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.62 EPS. As a group, sell-side analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.